- Poster presentation
- Open Access
UK paediatric rheumatology and its clinical trials network
© Beresford et al; licensee BioMed Central Ltd. 2008
- Published: 15 September 2008
- Orphan Drug
- Paediatric Rheumatology
- Clinical Trial Unit
- Trial Network
- Consumer Involvement
There is striking paucity of a rigorous evidence-base for the treatment of paediatric musculoskeletal diseases. The Medicines for Children Research Network (MCRN) improves coordination and quality of clinical trials and related studies across the UK. It has joined in partnership with the Arthritis Research Campaign (arc), the major UK charitable funder of musculoskeletal research, to form the MCRN/arc Paediatric Rheumatology CSG.
The MCRN has extensive expertise in supporting non-commercial, pharmaceutical-sponsored and investigator-led studies. The CSG is a multi-disciplinary group comprising clinicians, academics, basic scientist, pharmacy, and clinical trials unit support. Through consultation with stakeholders, its remit includes: developing a comprehensive portfolio for clinical trials/related studies covering the spectrum of paediatric rheumatology; ensuring consumer involvement; upholding Good Clinical Practice.
Topic Specific Group
Auto Inflammatory Diseases
Juvenile idiopathic arthritis (JIA)
Rare disorders (Initial focus on Scleroderma)
Uveitis in JIA
Formulations & Pharmacy
Studies recently adopted by MCRN
Prevention and treatment of steriod-induced osteopaenia in children and adolescents with rheumatic diseases
UK JSLE Cohort Study and Repository
UK Juvenile-onset Systemic Lupus Erythematosis Cohort Study epository: Clinical Characteristics and Immunopathology of Juvenile-onset SLE
A randomised clinical trial of mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA associated vasculitis
A study of the immunological and genetic mechanisms of response, and psychological response to, standard disease management in juvenile idiopathic arthritis (JIA)
An integrated national research network provides an excellent infrastructure to collaborate closely with international trial networks (e.g. CARRA, PRINTO) while fostering a unique contribution to the transformation of clinical care of children.
This article is published under license to BioMed Central Ltd.